BioXcel Therapeutics (BTAI) Misses Q2 EPS by 16c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($1.83), $0.16 worse than the analyst estimate of ($1.67). Revenue for the quarter came in at $457 thousand versus the consensus estimate of $420.56 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral